EGFR and neoplasm: Yet, the cases with EGFRm+ NSCLCs with concomitant de novo high-level MET amplification at baseline [20,32,72,89,91,92] may suggest tumor polyclonality, including heterogeneous clones with either mutated EGFR or amplified MET as a driver [6].